CHESTER, N.J. and SLOUGH, England, Dec. 21 /PRNewswire-FirstCall/ -- Reckitt Benckiser Group plc (RB.L) ("Reckitt Benckiser"), today commenced its previously announced cash tender offer (the "Offer") for all of the outstanding shares of Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) ("Adams").
As announced on December 10, 2007, Reckitt Benckiser has entered into a definitive agreement under which it will offer Adams stockholders US$60.00 in cash for each Adams share they hold. This offer is being made through Twickenham Inc., a wholly owned subsidiary of Reckitt Benckiser. Adams' Board of Directors has unanimously determined that the offer is fair to and in the best interests of Adams' stockholders and recommended that holders of Adams common stock accept the offer and tender their shares in the offer.
The Offer represents a total offer value of approximately US$2.3 billion (1.1 billion pounds Sterling), and will expire on January 23, 2008, unless extended.
The Offer is made directly to the stockholders of Adams and is conditioned upon, among other things, the tender of a majority of Adams' outstanding shares of common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Any common shares not acquired in the Offer are expected to be acquired in a subsequent merger at the same price as the Offer.
Stockholders of Adams are advised to read the important information
contained in the Tender Offer Statement on Schedule TO, the Offer to
Purchase and any other documents relating to the Offer that are filed by
Reckitt Benckiser and Twickenham with the Securities and Exchange
Commission (SEC). In addition, Adams will file with the SEC a
Solicitation/Re
'/>"/>
| SOURCE Reckitt Benckiser Group plc Copyright©2007 PR Newswire. All rights reserved |